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Background:  Recent  evidence  indicates  that chronic  heart failure  (CHF)  is  accompanied  by  both  activation
of  the  immune  system  and  autonomic  imbalance.  There  is  a  growing  body  of evidence  that  increased
levels  of proinﬂammatory  cytokines  and  other  inﬂammatory  markers  have  important  roles  as  mediators
of  disease  progression  and  markers  of  mortality  in  patients  with  CHF.
Objective:  The  aim  of this  study  was  to  investigate  connection  between  autonomic  imbalance  [obtained
by  analysis  of  heart  rate  variability  (HRV)]  and activation  of  the  immune  system  [as  measured  by  serum
levels  of tumor  necrosis  factor  (TNF)-]  in patients  with  chronic  heart  failure.
Materials  and  methods:  This  cross-sectional  study  included  21  patients  with  CHF and  8 age- and  gender-
matched  healthy  control  subjects.  We  assessed  HRV  by  24-hour  electrocardiographic  Holter  monitoring
and  measured  serum  levels  of TNF-  using  an  enzyme-linked  immunosorbent  assay.  Clinical  assessment
and  echocardiography  were  also performed.
Results:  There  was  an  inverse  correlation  between  serum  level  of  TNF- and  a time-domain  parameter
of  HRV  – SDNN  (r  =  −0.542,  p < 0.05).  A similar  result  was  found  for  HRV  triangular  index,  a geometric
measure  of  HRV  (r = −0.556;  p < 0.05).  The  correlation  was  stronger  for subjects  with  a diabetes  mellitus,
females,  and  TNFA2  allele  carriers  (an  “A”  at position  −308A).  The  pNN50,  indirect  marker  of cardiac
vagal  activity,  was  not  signiﬁcantly  associated  with serum  concentration  of  TNF-.
Conclusions:  In  conclusion,  the  results  of  the  present  study  indicate  that increased  serum  TNF-  level  is
signiﬁcantly  associated  with  reduced  HRV  indices,  suggesting  that  activation  of the immune  system  in
patients  with  CHF  is closely  related  to autonomic  imbalance.
3  Jap© 201
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Activation of the immune system and persistent inﬂammation
re important features of chronic heart failure (CHF), as evidenced
y increased circulating levels of pro- and anti-inﬂammatory
ytokines [1–4]. Autonomic imbalance and immune activation are
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temporally related [5], occurring concomitantly in the early stage of
the natural history of CHF [6,7], or in the period of asymptomatic left
ventricular dysfunction [8], irrespective of the CHF etiology [9,10].
Only in certain cases, serum levels of cytokines could be etiology or
disease-speciﬁc [11].
However, mechanisms of immune activation and loss of auto-
nomic balance in CHF are not completely understood. Tracey
described the cholinergic anti-inﬂammatory pathway which con-
trols cytokine production via parasympathetic or vagal nerve
activity [12]. Stimulation of the vagus nerve by either pharma-
cological [13] or electrical methods [14,15] signiﬁcantly inhibited
tumor-necrosis-factor (TNF)- release in experimental animals.
vier Ltd. All rights reserved.
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Table 1
Comparison of characteristics between study and control groups.
Study patients Control patients p
Age 64.86 ± 11.79 56.25 ± 7.19 0.027*
Sex
Male 14 (66.7%) 5 (62.5%)
0.833Female 7 (33.3%) 3 (37.5%)
TNF  (pg/mL) 5.82 ± 1.65 4.30 ± 2.72 0.008**
EF 0.32 ± 0.09 0.65 ± 0.02 0.000***
EDD (mm)  62.98 ± 7.65 50.33 ± 4.03 0.000***
ESD (mm) 47.76 ± 10.77 30.50 ± 3.34 0.003**
LA (mm) 44.76 ± 6.59 35.67 ± 2.34 0.000***
RVSP (mmHg) 33.05 ± 8.56 24.00 ± 5.29 0.092
HR  holter (bpm) 69.52 ± 10.34 72.50 ± 10.90 0.500
SDNN 81.39 ± 26.25 146.21 ± 26.34 0.000***
DaySDNN (8 am–9 pm) 80.74 ± 29.71 119.60 ± 35.41 0.008**
NightSDNN (11 pm–6 am) 71.96 ± 27.23 123.11 ± 29.26 0.000***
SDSD (ms) 31.88 ± 21.37 31.09 ± 13.98 0.924
TINN (ms) 340.30 ± 150.02 595.727 ± 172.68 0.001***
SDANN (ms) 68.73 ± 22.42 135.78 ± 26.38 0.000***
SDNNindex (bpm) 34.23 ± 15.58 44.89 ± 10.03 0.087
HRVi 10.51 ± 4.56 20.00 ± 4.20 0.000***
pNN50 (%) 8.54 ± 10.09 8.00 ± 4.38 0.851
* p < 0.5.
** p < 0.01.
*** p < 0.001.
Table 2
Study patient characteristics.
Study patients
Beta-blocker 21 (100%)
ACE/ARB 14 (66.7%)
Digoxin 6 (28.6%)
Spironolactone 12 (57.1%)
Amiodarone 8 (38.1%)
Sodium (mmol/L) 139.80 ± 4.58
Cholesterol (mmol/L) 4.45 ± 1.65
LDL  (mmol/L) 2.75 ± 1.98
HDL (mmol/L) 1.12 ± 0.18
Triglycerides (mmol/L) 1.17 ± 0.42
Creatinine (mol/L) 99.21 ± 70.80
Urea (mmol/L) 9.11 ± 8.90
By  pass 3 (14.3%)
Percutaneous coronary intervention 3 (14.3%)
Chronic stable coronary artery disease 11 (52.4%)
Previous myocardial infarction 12 (57.1%)
Diabetes mellitus 8 (38.1%)
Hypertension 14 (66.7%)
Dyslipidemia 16 (76.2%)8 V.N. Nikolic et al. / Journa
urthermore, cholinergic agents inhibited cytokine release from
uman macrophages. It has been suggested that acetylcholine
eleased after vagus nerve stimulation signiﬁcantly inhibited
elease of cytokines via a mechanism that required expression of
he 7 subunit of the nicotinic acetylcholine receptor [15]. There-
ore, when vagus nerve activity is decreased or absent, cytokines
re overproduced.
Tumor necrosis factor- is a proinﬂammatory cytokine involved
n the pathogenesis and the progression of CHF. High circulat-
ng levels of this cytokine are found in patients with heart failure
16,17] showing a positive correlation with disease severity [2,3].
he level of TNF- production is in part determined by promoter
ene polymorphism. A polymorphism at the nucleotide position
308 G/A in the promoter region affects the expression of TNF-
 gene (G = TNFA1, A = TNFA2). A TNFA2 allele is associated with
igh TNF- production due to high transcriptional activation [18].
he frequency of TNFA2 allele is more prevalent in patients with
heumatoid arthritis and systemic lupus erythematosus than in
ealthy controls [19]. There are few reports on TNF- polymor-
hism in patients with heart failure, but with inconclusive results
20–22].
The activity of autonomous nervous system (ANS), including
arasympathetic function, is difﬁcult to measure directly. A sophis-
icated, noninvasive and easy to perform method for assessing the
ctivity of the ANS is analysis of heart rate variability (HRV). This
imple method is useful for the evaluation of the sympatho-vagal
alance at the sinoatrial level, and has large prognostic value in
arious cardiovascular and non-cardiovascular disorders [23,24].
 large number of studies have provided evidence for a signiﬁcant
orrelation between lower HRV and increased mortality in patients
ith CHF [25–27].
The aim of this study was to investigate the connection between
he autonomic imbalance and low-grade inﬂammatory processes
n patients with CHF, by evaluating correlation between different
RV indices and serum levels of TNF-. Furthermore, we evaluated
he inﬂuence of −308 G/A TNF- polymorphism on time domain
ndices of HRV and plasma concentrations of TNF- in patients with
HF, respectively.
aterials and methods
The study protocol for this cross-sectional study was  approved
y the Ethics Committee of the University of Nis Faculty of
edicine, and Ethics Committee of Institute “Niska Banja”, in accor-
ance with the declaration of Helsinki. After receiving appropriate
nformation, all recruited patients gave both their written and ver-
al consent for participation in the study.
atient data
All patients had symptomatic congestive, but stable heart fail-
re [New York Heart Association (NYHA) functional class II or III]
ue to left ventricular systolic dysfunction. This was  conﬁrmed by
wo-dimensional echocardiography performed the same day when
lectrocardiogram Holter had been taken off and blood samples
aken for the biochemical analysis. Heart failure stage, i.e. NYHA
lass, was scored by the same investigator, after observation of each
atient at rest, dressing, walking, and climbing up the stairs and
anged from 1 (no limitations of physical activity) to 4 (unable to
arry on any physical activity) [28–30]. Ten patients (47.6%) were
lassiﬁed in NYHA I–II, and 11 subjects (52.4%) in NYHA III func-
ional class.
Characteristics of the study and control subjects are presented
n the Tables 1 and 2. The mean age of the two groups did not
igniﬁcantly differ.Smoking 6 (28.6%)
Inheritance 7 (33.3%)
Obesity 5 (23.8%)
The study group consisted of 14 (66.7%) male patients and 7
(30.4%) female patients. Three women (37.5%) were assessed in the
control group. All patients were stable with regard to symptoms
and therapy for at least 1 month before the measurements con-
ducted within this study, and in sinus rhythm. Exclusion criteria
were active infection, allergy, inﬂammatory diseases, cancer, and
treatment with anti-inﬂammatory drugs.
The patients were on standard medication consisting of
angiotensin-converting enzyme inhibitors/angiotensin II receptor
blockers (66.7%), diuretics (71.4%), spironolactone (57.1%), digoxin
(28.6%), beta-blockers (100.0%), low-dose aspirin (81.0%), statin
(76.2%), and amiodarone (38.1%). History of diabetes mellitus was
also assessed. Eight CHF patients (38.1%) had diabetes, and none in
the control group. The control group of patients consisted of healthy
subjects who did not use any medication prior to or during the
examination that might affect autonomic nervous activity.
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Smoking status was categorized as non-smoker or former
moker, and current smoker.
eart rate variability analysis
An ambulatory two-channel 24-hour electrocardiogram was
ecorded from the patients during their everyday activities, using
he Del Mar  Avionics models 5268-505 MPA/RACQ RACQ: 2.15
Irvine, CA, USA), and analyzed according to the recommendations
f the Task Force of the European Society of Cardiology (ESC) and
he North American Society of Pacing (NASPE) [24].
Time-domain analysis refers to statistics that are derived
irectly from the measurement of the normal-to-normal (N-N)
ntervals (i.e. intervals between consecutive QRS complexes result-
ng from sinoatrial discharge) and to statistics calculated from the
ifferences between successive N-N intervals [23,24,28]. The fol-
owing time domain variables were computed for each subject:
tandard deviation of the normal-to-normal QRS intervals (SDNN),
he standard deviation of mean R-R intervals in 5-minute recor-
ings (SDANN), and proportion derived by dividing the number of
nterval differences of successive N-N intervals greater than 50 ms
y the total number of N-N intervals (pNN50). DaySDNN was mea-
ured during the day from 8 am until 9 pm,  while NightSDNN was
valuated in the night period from 11 pm to 6 am.  HRV triangular
ndex (HRVi), a geometric measure of HRV developed by Malik and
oworker [29] preferably computed on long term-recordings, is an
ndex of total variability such as SDNN and SDANN [24]. Triangu-
ar interpolation of NN intervals (TINN) is another geometric time
omain measure.
lood sampling and laboratory analyses
Blood samples were collected from each subject between 9 am
nd 10 am after a fasting period of at least 10 h. Concentration
f TNF- was measured using an enzyme-linked immunosorbent
ssay (ELISA) according to the manufacturer’s speciﬁcations (Biole-
end, Fell, Germany). The limit of detection for TNF levels was
 pg/ml. All samples were measured in duplicates.
All of the assays were performed in the laboratory for functional
enomics and proteomics, Research Center for Biomedicine, and
echnicians were blinded to the clinical characteristics and out-
omes of the patients.
dentiﬁcation of the TNF-  ˛ gene polymorphism and genotyping
Genomic DNA was isolated from the whole blood taken on
thylenediaminetetraacetic acid and from peripheral blood smear
sing conventional methods of sodium dodecyl sulfate lyses, pro-
einase K digestion, phenol/chloroform extraction, and ethanol
recipitation and also using Quiagen DNA Isolation Kit (Quiagen
mbH, Hilden, Germany). Bi-allelic polymorphism (G/A substitu-
ion) within the TNF- gene was determined by polymerase chain
eaction – restriction fragment long polymorphism technique. The
egions containing the TNF--308 locus were ampliﬁed using the
rimers TNF--308-1 (5′-AGGCAATAGGTTTTGAGGGCCAT-3′) and
NF--308-2 (5′-ACACTCCCCATCCTCCCTGCT-3′). A 117 base pair
bp) polymerase chain reaction (PCR) product was generated using
he following reaction conditions: initiation at 95 ◦C for 15′; 35
able 3
orrelations between TNF level and HRV parameters.
SDNN DaySDNN (8 am–9 pm) NightSDNN (11 pm–6 am)  SDANN (ms
r −0.542 −0.444 −0.529 −0.426 
p  0.011* 0.065 0.024* 0.069 
* p < 0.05.diology 62 (2013) 37–43 39
cycles of denaturation at 94 ◦C for 1′; annealing at 50 ◦C for 1′ and
extension temperature 72 ◦C for 1′; ending with 4 ◦C. PCR products
were analyzed electrophoretically in 2% agarose gel and visualized
under ultraviolet light. The ampliﬁed DNA was  incubated with NcoI
and the treated fragments were analyzed by 8% polyacrylamide gel
and visualized by way  of silver staining. Interpretation was  as fol-
lows: a single band at 117 bp identiﬁed individuals homozygous for
adenine at TNF- 7308 locus; two  bands at 97 and 20 bp identiﬁed
individuals homozygous for guanine; three bands at 117, 97 and
20 bp identiﬁed individuals heterozygous at the TNF--308 locus.
Statistical analysis
The data analysis was  performed by Statistical Package for
Social Sciences (SPSS 16.0; Chicago, IL, USA). Baseline character-
istics are presented as frequencies or means with SDs. Student’s
t-test and ANOVA were used for comparing the groups’ character-
istics with normal distribution. Nonparametric data were analyzed
using Chi-square test or two-tailed Fisher’s exact test. The associa-
tion between TNF- levels and HRV parameters was evaluated by
Pearson correlation analysis. A p-value less than 0.05 was  consid-
ered to be a measure of statistical signiﬁcance for all statistical tests
used.
Results
Correlation between HRV parameters and TNF-  ˛ levels
The ﬁrst goal of this study was to ﬁnd a correlation between
TNF- level and both echocardiography and HRV parameters. The
Pearson’s correlation coefﬁcients with signiﬁcance levels for the
correlations between various HRV measures and TNF- levels are
shown in Table 3. TNF- levels were signiﬁcantly and inversely
correlated with a time-domain parameter of long-term variabil-
ity SDNN (r = −0.542, p < 0.05). A similar result was  found for HRVi,
a geometric measure of HRV (r = −0.556; p < 0.05). However, the
correlation between TNF- levels and heart rate (HR) was not
signiﬁcant (p = 0.828). Stronger correlations were found in female
patients (SDNN: r = −0.940, p < 0.01; SDANN: r = −0.826, p < 0.05)
and patients with diabetes mellitus (DM) (SDNN: r = −0.961,
p < 0.001). The pNN50, an indirect marker of cardiac vagal activ-
ity, was not signiﬁcantly correlated with plasma concentration of
TNF-.
The mean plasma TNF- level was 5.82 ± 1.65 pg/mL. We  clas-
siﬁed patients into a high TNF- group (≥5.50 pg/mL) and a low
TNF- group (<5.50 pg/mL) and compared variables in these groups
(Table 4). There were no signiﬁcant differences in age, mean
arterial BP, heart rate (HR), sodium levels, and creatinine levels
among the two  groups of patients. When comparing HRV param-
eters across the two  TNF- groups, signiﬁcantly lower values for
nearly all HRV variables (SDNN, Night SDNN, SDANN, TINN, and
HRVi), were associated with lower TNF- level. Two  subgroups of
patients, classiﬁed according to the plasma TNF- level, did not
differ signiﬁcantly in NYHA functional class, and furthermore, the
use of -blockers, angiotensin-converting enzyme inhibitors, digi-
talis (digoxin), spironolactone, and amiodarone was similar in both
groups. As shown, higher TNF- was  associated with diabetes mel-
litus.
) SDNNindex (bpm) HRVi pNN50 (%) SDSD (ms) TINN (ms)
−0.365 −0.556 −0.177 −0.079 −0.510
0.113 0.011* 0.483 0.756 0.031*
40 V.N. Nikolic et al. / Journal of Ca
Table 4
Differences in patient characteristics between patients with low and high TNF
plasma levels (below and above mean TNF).
Low TNF High TNF p
Number of patients (%) 12 (57.1%) 9 (42.9%)
Age 62.67 ± 11.87 67.78 ± 11.70 0.338
Systolic BP (mmHg) 134.83 ± 22.67 130.00 ± 14.14 0.565
Diastolic BP (mmHg) 78.75 ± 11.10 84.38 ± 10.50 0.272
EF  0.31 ± 0.10 0.34 ± 0.07 0.465
EDD  (mm) 65.00 ± 9.17 60.28 ± 4.07 0.132
ESD  (mm) 50.67 ± 13.23 43.89 ± 4.40 0.120
LA  (mm) 45.25 ± 8.20 44.11 ± 3.89 0.679
RVSP (mmHg) 31.67 ± 6.60 34.89 ± 10.81 0.407
HR  holter (bpm) 69.25 ± 12.08 69.89 ± 8.13 0.893
Sodium (mmol/L) 140.09 ± 3.73 139.44 ± 5.68 0.763
SDNN 91.52 ± 25.92 67.88 ± 20.97 0.032*
DaySDNN (8 am–9 pm) 88.93 ± 33.78 70.51 ± 21.49 0.200
NightSDNN 82.87 ± 31.35 58.32 ± 12.44 0.042*
SDSD (ms) 29.29 ± 20.51 35.12 ± 23.37 0.581
TINN (ms) 406.27 ± 158.49 257.84 ± 91.49 0.028*
SDANN (ms) 76.74 ± 21.37 57.71 ± 20.00 0.032*
SDNNindex (bpm) 36.74 ± 16.93 31.17 ± 14.11 0.441
HRVi 12.49 ± 4.65 8.09 ± 3.22 0.027*
pNN50 (%) 7.48 ± 6.49 9.60 ± 13.11 0.671
Cholesterol (mmol/L) 5.10 ± 1.84 3.51 ± 0.67 0.047*
LDL (mmol/L) 3.53 ± 2.45 1.78 ± 0.45 0.207
HDL  (mmol/L) 1.19 ± 0.20 1.02 ± 0.09 0.113
Triglycerides (mmol/L) 1.25 ± 0.50 1.06 ± 0.26 0.371
Creatinine (mol/L) 77.42 ± 17.78 126.45 ± 101.19 0.216
Urea (mmol/L) 6.10 ± 1.63 12.86 ± 12.65 0.176
ACE/ARB 7 (58.3%) 7 (77.8%) 0.510
Digoxin 5 (41.7%) 1 (11.1%) 0.125
Spironolactone 7 (58.3%) 5 (55.6%) 0.899
Amiodarone 5 (41.7%) 3 (33.3%) 0.697
NYHA
I–II  5 (41.7%) 5 (55.6%)
0.528III  7 (58.3%) 4 (44.4%)
TNF308
GG  6 (50.0%) 1 (11.1%)
0.061GA  6 (50.0%) 8 (88.9%)
By  pass 1 (8.3%) 2 (22.2%) 0.368
Percutaneous coronary
intervention
2 (16.7%) 1 (11.1%) 0.719
Chronic stable coronary artery
disease
5  (41.7%) 6 (66.7%) 0.256
Previous myocardial infarction 7 (58.3%) 5 (55.6%) 0.899
Diabetes mellitus 2 (16.7%) 6 (66.7%) 0.020*
Hypertension 6 (50.0%) 8 (88.9%) 0.095
Dyslipidemia 10 (83.3%) 6 (66.7%) 0.375
Smoking 5 (41.7%) 1 (22.2%) 0.125
D
a
b
t
t
i
a
circulating TNF- and indices of decreased HRV in patients with
mild-to-moderate heart failure. These authors showed that cir-
culating levels of TNF- are a stronger independent predictor of
depressed HRV than the circulating level of norepinephrine, which
T
DInheritance 3 (25.0%) 4 (44.4%) 0.350
Obesity 3 (25.0%) 2 (22.2%) 0.882
* p < 0.05.
istribution of TNF-  ˛ alleles and genotypes
The prevalence of the TNF- gene promoter polymorphism G/A
t position −308 seen in our study, is similar to the ones reported
y other investigators [31,32] (Table 5). The observed genotype dis-
ribution in HF patients did not show differences in comparison to
he control group of healthy unrelated, randomly selected normal
ndividuals: TNFA1/TNFA2 = 0.67/0.33 (CHF) or 0.62/0.38 (control)
s already published [20,33].
able 5
istribution of TNF- genotypes and alleles.
Genotype frequency 
TNF308 G/G TNF30
CHF frequency (number of patients) 0.67 (14) 0.33 (7
Control frequency (number of patients) 0.62 (5) 0.38 (3
2 = 0.045, p = 0.833 rdiology 62 (2013) 37–43
Plasma levels of TNF- were elevated in patients with
CHF compared with the control subjects (5.82 ± 1.65 pg/ml vs.
4.30 ± 2.72 pg/ml, p < 0.01). Our ﬁndings correspond to the results
of other studies [20,34,35]. After adding TNF- 308 genotype as
a discriminator, we  have found that higher plasma levels were
associated with TNFA2 genotype (TNFA1 vs. TNFA2) both in study
patients (4.62 ± 0.58 pg/ml vs. 6.42 ± 1.70 pg/ml, p < 0.01) and the
control group (2.05 ± 1.35 pg/ml vs. 5.66 ± 2.43 pg/ml, p < 0.05).
The HRV indices differed signiﬁcantly between TNFA1 and
TNFA2 carriers (Fig. 1). In line with our previous ﬁndings that TNF-
was inversely correlated with HRV measurements, and that TNF-
was lower in patients with TNFA1 genotype, we have found that the
TNF- gene promoter polymorphism G/A at position −308 carriers
had lower SDNN (p < 0.01), Night SDNN (p < 0.01), and SDNN index
(p < 0.05).
Discussion
In the present study, we conﬁrmed earlier observations, which
suggest an inverse correlation of TNF- levels with HRV indices
in patients with CHF. In our study, SDNN, SDANN, and HRVi were
signiﬁcantly and inversely correlated with plasma levels of TNF-
, indicating that higher serum TNF- levels were associated with
lower HRV. Stronger correlations were found in female patients,
patients with diabetes mellitus (DM) and TNFA2 allele (an “A” at
position −308A).
Our results are in accordance with those of Malave et al. [34]
who reported an inverse relationship between increased levels ofFig. 1. Heart rate variability parameters in patients with different tumor necrosis
factor (TNF) 308 genotypes.
Allele frequency
8 G/A TNF308 A/A TNF308 G TNF308 A
) 0.00 (0) 0.83 0.17
) 0.00 (0) 0.81 0.19
2 = 0.035, p = 0.851
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s encouraging for the possible existence of a direct relationship.
traburzyn´ska-Migaj et al. [36] reported the signiﬁcant negative
orrelations between time-domain HRV parameters and TNF- sol-
ble receptors (sTNF-RI, sTNF-RII) and IL-6 levels, respectively.
These ﬁndings are in contrast to a study in patients with decom-
ensated heart failure: there was strong evidence of an inverse
elation between HRV and IL-6 levels in systemic circulation whilst
NF- levels did not correlate with any of the HRV measures [37].
CHF is characterized by an ongoing inﬂammatory response
howing a positive correlation of inﬂammatory cytokines, such as
NF-, IL-1b, IL-6, IL-18, with disease severity and prognosis [1–3].
echanisms of immune activation in CHF are still indeterminate.
utonomic imbalance is closely related with them and, according
o our ﬁndings, might be partly also due to the immune activation.
TNF- is a potent proinﬂammatory cytokine released by most
ell types with pleiotropic effects. Since Levine and coworkers [17]
eported that the levels of TNF- were elevated in the settings
f CHF, several studies have shown a correlation between plasma
NF- levels and the progression of heart failure [16,38], due to car-
iac myocyte hypertrophy [39], contractile dysfunction [40], and
eft ventricular remodeling [3]. However, rapid TNF- biosynthe-
is by cardiac myocytes and nonmyocardial cell types within the
yocardium, and some of its protective effects in acute ischemic
njury, suggest that TNF- has a complex, yet not completely known
ole in heart diseases [41].
Some studies have provided evidence that cardiac production is
ot the main source of raised peripheral cytokine plasma concen-
rations, especially in patients with mild and moderate CHF [42,43],
nd that the bioactivity of TNF- in the serum could be modulated
y sTNF-Rs [44–46]. This suggests that induction of cytokines in the
yocardium is a relatively late event in the pathogenesis of CHF
nd partly explains contradictory results of human studies. How-
ver, plasma levels of TNF- correlates with mRNA expression in
he myocardium and thus may  serve as an appropriate marker of
yocardial cytokine activation in spite of inﬂuence by other fac-
ors, such as clearance and production of TNF- by nonmyocardial
issues [42].
HRV has demonstrated decreased parasympathetic and
ncreased sympathetic reactivity [47] and is associated with
levated inﬂammatory markers in patients with diabetes mellitus
48,49] or impaired glucose tolerance [50], hypertension [51,52],
ental depression [53], and coronary artery disease [54]. In the
ramingham study, SDNN was a signiﬁcant predictor of all-cause
ortality after adjusting for other risk factors [55]. SDNN and
DANN reﬂect both sympathetic and parasympathetic modulation
f HR and reduced SDANN and SDNN values usually indicate
elative sympathetic dominance [56].
The autonomic imbalance in heart failure, especially changes
n vagus nerve control of HR, become apparent at a very early
evelopmental stage of left ventricular dysfunction [57], and it
ould be an interesting target for new drugs in patients with
HF. After the evidence from experimental heart failure model
n efﬁcacy of electrical vagus nerve stimulation in CHF [58], the
rst-in-human study performed on 32 patients with CHF showed
igniﬁcant improvements in NYHA class, quality of life, 6-min walk
est, left ventricular ejection fraction, and left ventricular systolic
olumes [59,60]. Randomized controlled clinical trials of adequate
ize are needed for conﬁrming vagal nerve stimulation as a new
herapeutic strategy for CHF. Our ﬁndings suggest that chronic
ow-grade systemic inﬂammation which accompanies autonomic
mbalance in CHF could be a useful marker for noninvasive
election of patients who could beneﬁt from vagal nerve stimu-
ation or immunological-mediated therapies such as non-speciﬁc
mmunomodulation therapy or intravenous immunoglobulins [61].
It should be noted that there are important limitations to inter-
retation of the present ﬁndings. First, the number of controldiology 62 (2013) 37–43 41
patients was relatively small in size in comparison with study
patients. But, even though, we  are conﬁdent that restrictive
inclusion criteria, determined homoscedasticity of variance prior
analysis, and homogeneity of obtained results for control patients
can be enough for valid statistical comparison with study patients.
In addition, some similar designed experiments [34] in their analy-
ses used quite similar sample sizes. Another limitation of the study
is that only one cytokine was  analyzed. Although there is consid-
erable interest in examining different proinﬂammatory cytokines
in CHF patients as they are biomarkers of disease severity and
prognosis, TNF- is considered to be one of the main predictors
of worsening heart failure and increasing mortality. In a recently
published review [62], the authors summarized a large number of
signiﬁcant studies where the role of various inﬂammatory biomark-
ers in heart failure was  studied. In the vast majority of them, TNF-
was posited as one of the most speciﬁc cytokines related to heart
failure, since its plasma elevation signiﬁcantly correlates with both
disease progression and prediction. In line with this fact is the evi-
dence that administration of TNF- to experimental animals or its
transgenic over expression can replicate the heart failure pheno-
type [63,64], which further supports the importance of the role of
TNF- in the disease. Taking all this into consideration, we have
chosen this cytokine to analyze and to evaluate its relation with
HRV. However, our study does not consider other cytokines to be
less signiﬁcant nor preclude their role in pathophysiology of heart
failure.
The present study reports novel ﬁndings regarding the inﬂu-
ence of polymorphisms −308 A/G. Even though we have found
signiﬁcant correlation of both autonomic imbalance assessed by
HRV and TNF- level with polymorphisms −308 A/G, these results
also should be taken with reserve considering the relatively small
sample size.
In conclusion, the results of the present study indicate that an
increased serum TNF- is signiﬁcantly associated with reduced
HRV indices, suggesting that activation of the immune system in
patients with CHF is closely related to autonomic imbalance.
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